JP2023541671A - シヌクレイノパチーの処置のためのアルファ-シヌクレインワクチン - Google Patents
シヌクレイノパチーの処置のためのアルファ-シヌクレインワクチン Download PDFInfo
- Publication number
- JP2023541671A JP2023541671A JP2023517699A JP2023517699A JP2023541671A JP 2023541671 A JP2023541671 A JP 2023541671A JP 2023517699 A JP2023517699 A JP 2023517699A JP 2023517699 A JP2023517699 A JP 2023517699A JP 2023541671 A JP2023541671 A JP 2023541671A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- alpha
- synuclein
- peptide
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079819P | 2020-09-17 | 2020-09-17 | |
| US63/079,819 | 2020-09-17 | ||
| PCT/US2021/045055 WO2022060487A1 (en) | 2020-09-17 | 2021-08-06 | Alpha-synuclein vaccine for the treatment of synucleinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023541671A true JP2023541671A (ja) | 2023-10-03 |
| JP2023541671A5 JP2023541671A5 (cg-RX-API-DMAC7.html) | 2024-08-14 |
Family
ID=80777122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023517699A Pending JP2023541671A (ja) | 2020-09-17 | 2021-08-06 | シヌクレイノパチーの処置のためのアルファ-シヌクレインワクチン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230355756A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4213867A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023541671A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230087487A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116783211A (cg-RX-API-DMAC7.html) |
| AR (1) | AR123189A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021344230A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3192429A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301224A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023003007A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202227465A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022060487A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025507875A (ja) | 2022-02-28 | 2025-03-21 | トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー | 少なくともβ-グルカン若しくはマンナンからなるか、又はこれを含む結合体 |
| CN119136838A (zh) | 2022-02-28 | 2024-12-13 | 特瑞德姆生物科技有限责任两合公司 | 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物 |
| JP2026521182A (ja) | 2023-06-15 | 2026-06-26 | スリーエム イノベイティブ プロパティズ カンパニー | プライマー組成物、接着剤システム、及び関連プロセス |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010526028A (ja) * | 2007-02-23 | 2010-07-29 | エラン・フアーマシユーチカルズ・インコーポレーテツド | シヌクレイノパチーおよびアミロイド形成疾患(amyloidogenicdisease)の予防および処置 |
| JP2015527369A (ja) * | 2012-08-21 | 2015-09-17 | インスティテュート フォー モレキュラー メディシン, インコーポレイテッド | アミロイド、タウおよびα−シヌクレインの沈着に関連する疾患に関する組成物および方法 |
| JP2015536347A (ja) * | 2012-11-16 | 2015-12-21 | ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | 淋菌性MtrEペプチドおよびワクチン |
| WO2018232369A1 (en) * | 2017-06-16 | 2018-12-20 | United Neuroscience | Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies |
| WO2019084118A2 (en) * | 2017-10-25 | 2019-05-02 | Janssen Pharmaceuticals, Inc. | PHOSPHORYLATED TUBE PEPTIDE COMPOSITIONS AND USES THEREOF |
| WO2019226941A1 (en) * | 2018-05-23 | 2019-11-28 | Gritstone Oncology, Inc. | Shared antigens |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2657953A1 (en) * | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| LT3067066T (lt) * | 2007-02-23 | 2019-06-25 | Prothena Biosciences Limited | Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas |
| US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| CA2697373C (en) * | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
| JP7136790B2 (ja) * | 2017-02-17 | 2022-09-13 | ブリストル-マイヤーズ スクイブ カンパニー | アルファ-シヌクレインに対する抗体およびその使用 |
| EP3692373A1 (en) * | 2017-10-02 | 2020-08-12 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies |
-
2021
- 2021-08-06 CA CA3192429A patent/CA3192429A1/en active Pending
- 2021-08-06 JP JP2023517699A patent/JP2023541671A/ja active Pending
- 2021-08-06 EP EP21869943.7A patent/EP4213867A4/en active Pending
- 2021-08-06 IL IL301224A patent/IL301224A/en unknown
- 2021-08-06 KR KR1020237012532A patent/KR20230087487A/ko active Pending
- 2021-08-06 CN CN202180064031.1A patent/CN116783211A/zh active Pending
- 2021-08-06 MX MX2023003007A patent/MX2023003007A/es unknown
- 2021-08-06 US US18/245,533 patent/US20230355756A1/en active Pending
- 2021-08-06 AU AU2021344230A patent/AU2021344230A1/en active Pending
- 2021-08-06 WO PCT/US2021/045055 patent/WO2022060487A1/en not_active Ceased
- 2021-08-09 AR ARP210102220A patent/AR123189A1/es unknown
- 2021-08-09 TW TW110129346A patent/TW202227465A/zh unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010526028A (ja) * | 2007-02-23 | 2010-07-29 | エラン・フアーマシユーチカルズ・インコーポレーテツド | シヌクレイノパチーおよびアミロイド形成疾患(amyloidogenicdisease)の予防および処置 |
| JP2015527369A (ja) * | 2012-08-21 | 2015-09-17 | インスティテュート フォー モレキュラー メディシン, インコーポレイテッド | アミロイド、タウおよびα−シヌクレインの沈着に関連する疾患に関する組成物および方法 |
| JP2015536347A (ja) * | 2012-11-16 | 2015-12-21 | ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | 淋菌性MtrEペプチドおよびワクチン |
| WO2018232369A1 (en) * | 2017-06-16 | 2018-12-20 | United Neuroscience | Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies |
| WO2019084118A2 (en) * | 2017-10-25 | 2019-05-02 | Janssen Pharmaceuticals, Inc. | PHOSPHORYLATED TUBE PEPTIDE COMPOSITIONS AND USES THEREOF |
| WO2019226941A1 (en) * | 2018-05-23 | 2019-11-28 | Gritstone Oncology, Inc. | Shared antigens |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4213867A1 (en) | 2023-07-26 |
| AU2021344230A1 (en) | 2023-04-13 |
| EP4213867A4 (en) | 2025-04-09 |
| TW202227465A (zh) | 2022-07-16 |
| CA3192429A1 (en) | 2022-03-24 |
| US20230355756A1 (en) | 2023-11-09 |
| CN116783211A (zh) | 2023-09-19 |
| IL301224A (en) | 2023-05-01 |
| KR20230087487A (ko) | 2023-06-16 |
| WO2022060487A1 (en) | 2022-03-24 |
| AR123189A1 (es) | 2022-11-09 |
| MX2023003007A (es) | 2023-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11965005B2 (en) | Multi-epitope vaccine for the treatment of Alzheimer's disease | |
| US20250186567A1 (en) | Multiepitope vaccine for the treatment of alzheimer's disease | |
| JP2023541669A (ja) | アルツハイマー病の処置のためのβ-アミロイドワクチン | |
| JP2023541670A (ja) | アルツハイマー病の処置のためのマルチエピトープワクチン | |
| US20230302127A1 (en) | Tau vaccine for the treatment of alzheimer's disease | |
| US20230355756A1 (en) | Alpha-synuclein vaccine for the treatment of synucleinopathies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240805 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240805 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250730 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251027 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260130 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260413 |